Guillaume S.
- Country
- France
- Department
- Hepato-Gastroenterology Department
Research Overview
- Evaluation of Autologous Adipose Tissue-Derived Stromal Vascular Fraction and Microfat for Refractory Perianal Crohn's Fistulas
- Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Oral Ozanimod for Maintenance in Moderately to Severely Active Crohn's Disease
- A Randomized Controlled Trial Comparing Azathioprine and Methotrexate in Combination with Adalimumab for Endoscopic Response in Crohn's Disease Patients
Data & Insights
Has run more than one trial at 32 of 175 partner sites.
Specializations
Inflammatory Bowel Disease Management
The investigator specializes in treating complex manifestations of Crohn's disease and ulcerative colitis, with particular emphasis on innovative therapeutic approaches.
- Complex perianal fistulas in Crohn's disease
- Moderately to severely active ulcerative colitis
- Advanced Crohn's disease therapeutics
Research focus includes evaluation of novel biological treatments and combination therapies for inflammatory bowel conditions.
Cell-Based Therapies
Expertise in autologous cell therapy applications, particularly investigating stromal vascular fraction and microfat treatments for complex gastrointestinal conditions.
- Adipose-derived therapeutic approaches
- Local injection techniques
- Regenerative medicine applications
Clinical interest extends to developing innovative cellular therapies for refractory gastrointestinal conditions.
Treatment Optimization
Focus on comparative therapeutic strategies and maintenance therapy optimization for inflammatory bowel diseases.
- Combination therapy assessment
- Novel therapeutic agents
- Long-term disease management
Expertise in evaluating treatment efficacy through clinical and endoscopic response measures.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.